Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 03:08PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-42.75 Insider Own5.83% Shs Outstand2.55M Perf Week-15.89%
Market Cap2.29M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.41M Perf Month-61.23%
Income-27.11M PEG- EPS next Q- Inst Own12.86% Short Float11.41% Perf Quarter-88.72%
Sales1.97M P/S1.16 EPS this Y- Inst Trans- Short Ratio3.26 Perf Half Y-92.88%
Book/sh-17.36 P/B- EPS next Y- ROA-198.99% Short Interest0.27M Perf Year-99.66%
Cash/sh0.20 P/C4.41 EPS next 5Y- ROE-584.20% 52W Range0.92 - 398.40 Perf YTD-91.91%
Dividend Est.- P/FCF- EPS past 5Y62.30% ROI- 52W High-99.77% Beta1.94
Dividend TTM- Quick Ratio0.10 Sales past 5Y-20.00% Gross Margin97.06% 52W Low-2.18% ATR (14)0.19
Dividend Ex-Date- Current Ratio0.10 EPS Y/Y TTM74.71% Oper. Margin-1905.88% RSI (14)21.86 Volatility11.28% 13.21%
Employees16 Debt/Eq- Sales Y/Y TTM144.31% Profit Margin-1373.61% Recom1.00 Target Price32.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q94.28% Payout- Rel Volume3.41 Prev Close0.96
Sales Surprise42.13% EPS Surprise-1867.60% Sales Q/Q-28.34% Earnings- Avg Volume84.32K Price0.90
SMA20-32.08% SMA50-59.81% SMA200-97.24% Trades Volume251,134 Change-6.25%
Date Action Analyst Rating Change Price Target Change
Sep-27-21Upgrade ROTH Capital Neutral → Buy $2.50 → $8
Jul-01-21Initiated Guggenheim Buy $8
Jun-01-21Initiated Cantor Fitzgerald Overweight $10
May-17-21Downgrade ROTH Capital Buy → Neutral
Mar-30-21Initiated B. Riley Securities Buy $15
Nov-14-19Initiated The Benchmark Company Speculative Buy $4
May-14-19Initiated ROTH Capital Buy
May-16-24 11:45PM
May-14-24 01:53PM
08:00AM Loading…
Apr-29-24 08:00AM
Mar-22-24 01:53PM
Mar-19-24 08:43AM
Jan-26-24 08:30AM
Jan-24-24 09:00AM
Jan-22-24 08:00AM
Jan-09-24 01:56PM
Jan-02-24 08:00AM
08:47AM Loading…
Dec-29-23 08:47AM
Dec-22-23 08:00AM
Dec-20-23 02:15PM
Dec-02-23 05:05AM
Dec-01-23 04:00PM
Nov-29-23 08:53AM
Nov-28-23 09:26PM
Nov-27-23 08:00AM
Nov-24-23 10:53AM
Nov-15-23 05:06AM
Oct-27-23 08:11AM
Oct-17-23 08:00AM
Sep-27-23 08:00AM
Sep-25-23 07:00AM
10:06AM Loading…
Sep-21-23 10:06AM
Sep-20-23 07:00AM
Sep-06-23 08:17PM
Aug-14-23 08:00AM
Aug-13-23 09:58AM
Jun-22-23 08:00AM
May-30-23 07:00AM
May-22-23 08:00AM
May-15-23 08:33AM
May-05-23 08:00AM
Apr-04-23 08:00AM
Mar-30-23 10:21AM
Mar-29-23 04:05PM
Mar-12-23 12:22PM
Mar-10-23 09:00AM
Feb-27-23 09:13AM
Feb-15-23 09:21AM
Feb-13-23 08:00AM
Feb-10-23 08:00AM
Feb-06-23 08:00AM
Dec-22-22 08:00AM
Dec-15-22 11:11AM
Dec-08-22 08:00AM
Nov-23-22 08:00AM
Nov-07-22 12:56PM
Nov-01-22 08:36AM
Oct-28-22 02:49PM
Oct-27-22 08:00AM
Oct-25-22 08:00AM
Sep-30-22 10:00AM
Sep-13-22 08:00AM
Sep-09-22 09:00AM
Aug-30-22 08:00AM
Aug-24-22 08:00AM
Jul-18-22 08:00AM
Jun-09-22 08:00AM
Jun-06-22 12:47PM
May-18-22 08:00AM
May-12-22 08:00AM
Apr-22-22 11:00AM
Apr-11-22 08:00AM
Mar-08-22 08:00AM
Mar-07-22 08:00AM
Feb-28-22 08:00AM
Dec-21-21 04:05PM
Dec-16-21 08:00AM
Dec-06-21 08:01AM
Nov-29-21 09:00AM
Nov-24-21 11:18AM
Nov-23-21 07:03AM
Nov-10-21 08:00AM
Nov-09-21 11:18AM
Nov-08-21 09:19AM
Nov-02-21 08:00AM
Oct-25-21 02:00PM
Oct-01-21 08:00AM
Sep-27-21 12:59PM
Sep-22-21 10:02AM
Sep-21-21 03:25PM
Sep-09-21 08:00AM
Sep-02-21 08:00AM
Sep-01-21 08:00AM
Aug-09-21 10:47AM
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mehra RajSee RemarksDec 01 '23Buy1.3275,75799,999185,142Dec 01 04:16 PM
Golembiewski Michael JosephChief Financial OfficerNov 30 '23Buy1.2183,000100,22286,450Dec 01 04:16 PM